Eyenovia Update on FDA-Approved Products

 Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye)

Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet®

https://www.biospace.com/article/releases/eyenovia-provides-clinical-and-scientific-update-on-fda-approved-products-mydcombi-and-clobetasol-propionate-ophthalmic-suspension/